An investigation on behalf of investors in American Renal Associates Holdings, Inc. (NYSE: ARA) shares over potential wrongdoing at American Renal Associates Holdings, Inc. was announced.
San Diego, CA -- (SBWIRE) -- 08/14/2019 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at American Renal Associates Holdings, Inc.
Investors who purchased shares of American Renal Associates Holdings, Inc. (NYSE: ARA) and currently hold any of those NYSE: ARA shares have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain American Renal Associates Holdings, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
On March 28, 2019, a lawsuit was filed against American Renal Associates Holdings, Inc. (NYSE: ARA) over alleged violations of Federal Securities Laws. The plaintiff alleged that the defendants violated Federal Securities Laws.
Those who purchased shares of American Renal Associates Holdings, Inc. (NYSE: ARA) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels